National Comprehensive Cancer Network



About NCCN

NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

The NCCN Clinical Practice Guidelines in Oncology™ for Esophageal Cancer and Gastric Cancer Have Been Updated and Published as Version 1.2010

Trastuzumab was added to Principles of Systemic Therapy in the NCCN Guidelines for Esophageal Cancer and for Gastric Cancer as an option when used in combination with systemic chemotherapy for the treatment of patients with advanced esophageal cancer, gastric cancer, or GE junction adenocarcinoma that is HER-2-positive as determined by a standardized method.

The NCCN Clinical Practice Guidelines in Oncology™ for Colon Cancer and Rectal Cancer Have Been Updated and Published as Version 1.2010

Several updates were made to the NCCN Guidelines for Colon Cancer and for Rectal Cancer based on BRAF gene status. Updates include a new section for BRAF testing added to the Principles of Pathologic Review. For patients with metastatic disease, consideration of tumor BRAF gene status was added to the workup recommendations as an option if KRAS is nonmutated. A new footnote was added stating that "Patients with a known V600E BRAF mutation appear to be unlikely to benefit from anti-EGFR monoclonal antibodies."

For the complete updated version of the NCCN Clinical Practice Guidelines in Oncology™, the NCCN Drugs & Biologics Compendium™, and the NCCN Chemotherapy Order Templates™ please visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved